A multicenter, randomized, double-blind, placebo-controlled study of subcutaneous Tovaxin in subjects with CIS or RR-MS.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study of subcutaneous Tovaxin in subjects with CIS or RR-MS.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2016

At a glance

  • Drugs Imilecleucel-T (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms OLETERMS; OLTERMS; TERMS
  • Sponsors Opexa Therapeutics
  • Most Recent Events

    • 14 Nov 2011 Results of the TERMS study were published in the Multiple Sclerosis Journal, according to an Opexa media release.
    • 28 Jun 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 28 Jun 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top